Don't get left behind! The modernized ClinicalTrials.gov is coming. Check it out now.
Say goodbye to ClinicalTrials.gov!
The new site is coming soon - go to the modernized ClinicalTrials.gov
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Crowd Sourcing Platform for Patients With Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03530826
Recruitment Status : Recruiting
First Posted : May 21, 2018
Last Update Posted : July 21, 2021
Sponsor:
Information provided by (Responsible Party):
Carl Anthony Blau, MD, All4Cure

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
All4Cure aims to accelerate learning about cancer by sharing medical information and research results from cancer patients with fellow cancer patients, oncologists, and scientists on the All4Cure website with the hope that together patients, clinicians and researchers can cure cancer faster.

Condition or disease Intervention/treatment
Cancer Other: No intervention

Detailed Description:
The core hypothesis tested by this study is that engaging researchers, clinicians and patients in an online knowledge sharing platform will enable patients to better understand cancer, better inform treatment decisions made by oncologists and accelerate cancer research. Leftover samples from patients with cancer (blood, bodily fluids and/or tissues collected for clinical purposes) will be obtained and sent for various types of analyses and results will be shared on the All4Cure website.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 5000 participants
Observational Model: Other
Time Perspective: Prospective
Target Follow-Up Duration: 10 Years
Official Title: A Crowd Sourcing Platform for Patients With Cancer
Actual Study Start Date : April 26, 2018
Estimated Primary Completion Date : January 31, 2028
Estimated Study Completion Date : January 31, 2028
Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Intervention Details:
  • Other: No intervention
    No Intervention

Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change in tumor tissue molecular profiles [ Time Frame: 6 years ]
    Profiles of pre- and post-treatment tumor tissue will be compared.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult cancer patients
Criteria

Inclusion Criteria:

  • Have been diagnosed with cancer.
  • Be under the care of a physician.
  • Be 18 years of age or older.

Exclusion Criteria:

Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03530826


Contacts
Layout table for location contacts
Contact: Carl A Blau, MD 2064121787 tony@all4cure.com
Contact: Kimberly A Burton, PhD 2069482711 kaburton@all4cure.com

Locations
Layout table for location information
United States, Washington
All4Cure Recruiting
Seattle, Washington, United States, 98136
Contact: Carl A Blau, MD    206-412-1787    tony@all4cure.com   
Contact: Kimberly A Burton, PhD    2069482711    kaburton@all4cure.com   
Sponsors and Collaborators
All4Cure
Investigators
Layout table for investigator information
Principal Investigator: Carl A Blau, MD All4Cure
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Layout table for additonal information
Responsible Party: Carl Anthony Blau, MD, Principal Investigator, All4Cure
ClinicalTrials.gov Identifier: NCT03530826    
Other Study ID Numbers: All4Cure01
First Posted: May 21, 2018    Key Record Dates
Last Update Posted: July 21, 2021
Last Verified: July 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: nonidentifiable clinical and research data may be shared with other researchers.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No